Weekly Digest – January 2026 Weekly Digest – January 2026 05 January 2026: Kelun-Biotech announces Breakthrough Therapy Designation granted in China for Sacituzumab Tirumotecan (sac-TMT) in combination with immunotherapy Pembrolizumab for first-Line treatment of PD-L1-positive NSCLC The Company has reached […]
Weekly Digest – January 2026 Weekly Digest – January 2026 4 January 2026: Kelun-Biotech receives Investigational New Drug Approval for ITGB6-targeted ADC SKB105 from the NMPA Kelun-Biotech has achieved a key regulatory milestone with the approval of an Investigational New […]
Weekly Digest – January 2026 Weekly Digest – January 2026 8 January 2026: Whitehawk Therapeutics advances to clinical stage with IND clearance for HWK-007 and announces IND Submission for HWK-016 Whitehawk Therapeutics received FDA clearance for its PTK7-targeted ADC HWK-007, […]
